Alacizumab pegol
Alacizumab pegol (pronunciation: al-a-siz-u-mab pe-gol) is a monoclonal antibody designed for the treatment of various autoimmune diseases. It is a type of biopharmaceutical that is developed through biological processes, rather than chemical synthesis.
Etymology
The name "Alacizumab pegol" is derived from the International Nonproprietary Names (INN), where "Ala-" refers to the target of the drug, "-cizu-" is a stem used for humanized antibodies, "-mab" is a common suffix for monoclonal antibodies, and "pegol" indicates that the drug is a PEGylated protein.
Pharmacology
Alacizumab pegol works by binding to a specific target on the surface of certain cells in the immune system. This binding action can block the activity of these cells, which are often involved in the development of autoimmune diseases.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Autoimmune disease: A condition in which your immune system mistakenly attacks your body.
- Biopharmaceutical: A type of drug produced using biotechnology.
- PEGylation: The process of attaching the polymer polyethylene glycol (PEG) to a molecule, in this case, a protein.
See Also
External links
- Medical encyclopedia article on Alacizumab pegol
- Wikipedia's article - Alacizumab pegol
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski